{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:53Z","timestamp":1781646953583,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Endocrine immune-related adverse events (irAEs) are increasingly encountered with immune checkpoint inhibitors (ICIs), yet patterns of screening, referral, and emergency outcomes remain underexplored. This study evaluated the adequacy of endocrine monitoring, iming of endocrinology involvement, and determinants of endocrine emergencies in ICI-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 103 patients (67 men, 36 women; mean age 60.8\u2009\u00b1\u200912.1 years) referred to the Endocrinology Department between 2016 and 2025. Clinical data, cancer types, immunotherapy regimens, hormonal assessments, and causes and timing of referral were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients (93.3%) were referred due to newly developed endocrine irAEs, with endocrinology involvement occurring at a median of 7.4 months (\u2248\u200910th therapy cycle) after ICI initiation. The predominant ICI regimen involved PD-1 inhibitors (66%). Thyroid dysfunction (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200964), secondary adrenal insufficiency (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928), and hyperglycemia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) were the leading endocrinopathies; hypophysitis was detected in 7 cases. Before ICI treatment, endocrine evaluation was absent in 22.3% and incomplete in 38.2%, while 9.7% received no endocrine follow-up during ICI therapy. Emergency admissions occurred in 17.4%, mainly due to adrenal crisis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), followed by thyrotoxicosis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093). Although baseline screening status and timing of endocrinology involvement were not associated with emergency risk, phenotype strongly influenced outcomes: central adrenal insufficiency increased risk (RR\u2009=\u20093.29; 95% CI 1.33\u20138.08;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0197).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Endocrine irAEs are frequent and may be recognized only after clinical deterioration, exposing patients to preventable endocrine emergencies, particularly adrenal crisis. These findings highlight heterogeneity and gaps in endocrine surveillance during ICI therapy and support early, structured oncologist\u2013endocrinologist collaboration with standardized baseline and follow-up assessments to improve patient safety and continuity of immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04589-5","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:44:17Z","timestamp":1775047457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-5981","authenticated-orcid":false,"given":"Selin","family":"Tekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda Hanife","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman Nahit","family":"Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"\u00dcnl\u00fct\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomris","family":"Erbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcuk","family":"Dagdelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"1","key":"4589_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"S. Bagchi, R. Yuan, E.G. Engleman, Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16(1), 223\u2013249 (2021). https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu. Rev. Pathol."},{"issue":"12","key":"4589_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"D.Y. Wang, J.-E. Salem, J.V. Cohen, S. Chandra, C. Menzer, F. Ye et al., Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4(12), 1721\u20131728 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol."},{"key":"4589_CR3","doi-asserted-by":"publisher","unstructured":"R. Barroso-Sousa, P.A. Ott, F.S. Hodi, (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management Jan 03. https:\/\/doi.org\/10.1002\/cncr.31200","DOI":"10.1002\/cncr.31200"},{"issue":"2","key":"4589_CR4","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","volume":"21","author":"R Hattersley","year":"2021","unstructured":"R. Hattersley, M. Nana, A.J. Lansdown, Endocrine complications of immunotherapies: a review. Clin. Med. 21(2), e212\u2013e22 (2021). https:\/\/doi.org\/10.7861\/clinmed.2020-0827","journal-title":"Clin. Med."},{"issue":"2","key":"4589_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop et al., Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4(2), 173\u2013182 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol."},{"key":"4589_CR6","doi-asserted-by":"publisher","first-page":"708195","DOI":"10.3389\/fonc.2021.708195","volume":"11","author":"Z Zhao","year":"2021","unstructured":"Z. Zhao, X. Wang, J. Qu, W. Zuo, Y. Tang, H. Zhu et al., Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: a systematic review and meta-analysis. Front. Oncol. 11, 708195 (2021). https:\/\/doi.org\/10.3389\/fonc.2021.708195","journal-title":"Front. Oncol."},{"issue":"9","key":"4589_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"F. Martins, L. Sofiya, G.P. Sykiotis, F. Lamine, M. Maillard, M. Fraga et al., Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Reviews Clin. Oncol. 16(9), 563\u2013580 (2019). https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat. Reviews Clin. Oncol."},{"issue":"7","key":"4589_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat. Reviews Endocrinol. 17(7), 389\u2013399 (2021). https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat. Reviews Endocrinol."},{"issue":"03","key":"4589_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J De Filette","year":"2019","unstructured":"De J. Filette, C.E. Andreescu, F. Cools, B. Bravenboer, B. Velkeniers, A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res. 51(03), 145\u2013156 (2019). https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm. Metab. Res."},{"issue":"3","key":"4589_CR10","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1530\/eje-19-0169","volume":"181","author":"F Albarel","year":"2019","unstructured":"F. Albarel, F. Castinetti, T. Brue, Management of endocrine disease: immune check point inhibitors-induced hypophysitis. Eur. J. Endocrinol. 181(3), R107\u2013R18 (2019). https:\/\/doi.org\/10.1530\/eje-19-0169","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4589_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","volume":"24","author":"P Iglesias","year":"2021","unstructured":"P. Iglesias, J.C. S\u00e1nchez, J.J. D\u00edez, Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 24(4), 630\u2013643 (2021). https:\/\/doi.org\/10.1007\/s11102-021-01141-8","journal-title":"Pituitary"},{"issue":"14","key":"4589_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2217\/imt-2021-0061","volume":"13","author":"SH O\u011fuz","year":"2021","unstructured":"S.H. O\u011fuz, U. \u00dcnl\u00fct\u00fcrk, S. Aksoy, T. Erbas, Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Immunotherapy. 13(14), 1157\u20131163 (2021). https:\/\/doi.org\/10.2217\/imt-2021-0061","journal-title":"Immunotherapy"},{"key":"4589_CR13","doi-asserted-by":"publisher","unstructured":"A. Kotwal, C. Haddox, M. Block, Y.C. Kudva, Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ open. Diabetes Res. Care. 7(1) (2019). https:\/\/doi.org\/10.1136\/bmjdrc-2018-000591","DOI":"10.1136\/bmjdrc-2018-000591"},{"key":"4589_CR14","doi-asserted-by":"publisher","unstructured":"M.C. Zatelli, A. Faggiano, A. Argentiero, R. Danesi, S. D\u2019Oronzo, S. Fogli et al., Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian association of medical oncology (AIOM), Italian association of medical diabetologists (AMD), Italian society of diabetology (SID), Italian society of endocrinology (SIE) and Italian society of Pharmacology (SIF) multidisciplinary group. Cancer Treat. Rev. 102734 (2024). https:\/\/doi.org\/10.1016\/j.ctrv.2024.102734","DOI":"10.1016\/j.ctrv.2024.102734"},{"issue":"6","key":"4589_CR15","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"E.S. Husebye, F. Castinetti, S. Criseno, G. Curigliano, B. Decallonne, M. Fleseriu et al., Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur. J. Endocrinol. 187(6), G1\u2013G21 (2022). https:\/\/doi.org\/10.1530\/eje-22-0689","journal-title":"Eur. J. Endocrinol."},{"issue":"36","key":"4589_CR16","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"B.J. Schneider, J. Naidoo, B.D. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat et al., Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39(36), 4073\u20134126 (2021). https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"4589_CR17","doi-asserted-by":"publisher","first-page":"121738","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"J. Haanen, M. Obeid, L. Spain, F. Carbonnel, Y. Wang, C. Robert et al., Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann. Oncol. 33(12), 121738 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann. Oncol."},{"issue":"17","key":"4589_CR18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jop.18.00005","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino et al., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 36(17), 1714\u20131768 (2018). https:\/\/doi.org\/10.1200\/jop.18.00005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"4589_CR19","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","volume":"6","author":"S Paschou","year":"2021","unstructured":"S. Paschou, K. Stefanaki, T. Psaltopoulou, M. Liontos, K. Koutsoukos, F. Zagouri et al., How we treat endocrine complications of immune checkpoint inhibitors. ESMO open. 6(1), 100011 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2020.100011","journal-title":"ESMO open."},{"issue":"7","key":"4589_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1507\/endocrj.ej19-0163","volume":"66","author":"H Arima","year":"2019","unstructured":"H. Arima, S. Iwama, H. Inaba, H. Ariyasu, N. Makita, M. Otsuki et al., Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan endocrine society. Endocr. J. 66(7), 581\u2013586 (2019). https:\/\/doi.org\/10.1507\/endocrj.ej19-0163","journal-title":"Endocr. J."},{"key":"4589_CR21","doi-asserted-by":"publisher","first-page":"847917","DOI":"10.3389\/fonc.2022.847917","volume":"12","author":"SA Paschou","year":"2022","unstructured":"S.A. Paschou, M. Liontos, E. Eleftherakis-Papaiakovou, K. Stefanaki, C. Markellos, K. Koutsoukos et al., Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front. Oncol. 12, 847917 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.847917","journal-title":"Front. Oncol."},{"key":"4589_CR22","doi-asserted-by":"publisher","unstructured":"X. Bai, X. Chen, X. Wu, Y. Huang, Y. Zhuang, Y. Chen et al., (2020) Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. Journal of Endocrinological Investigation. 2020;43:1473-83. https:\/\/doi.org\/10.1007\/s40618-020-01226-4","DOI":"10.1007\/s40618-020-01226-4"},{"key":"4589_CR23","doi-asserted-by":"publisher","unstructured":"M. Atkinson, A. Lansdown, Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best Pract. Res. Clin. Endocrinol. Metab. 36(3):101635. https:\/\/doi.org\/10.1016\/j.beem.2022.101635","DOI":"10.1016\/j.beem.2022.101635"},{"issue":"7","key":"4589_CR24","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ec-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"C.E. Higham, A. Olsson-Brown, P. Carroll, T. Cooksley, J. Larkin, P. Lorigan et al., SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connections. 7(7), G1\u2013G7 (2018). https:\/\/doi.org\/10.1530\/ec-18-0068","journal-title":"Endocr. Connections"},{"issue":"3","key":"4589_CR25","doi-asserted-by":"publisher","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","volume":"2","author":"M Girotra","year":"2018","unstructured":"M. Girotra, A. Hansen, A. Farooki, D.J. Byun, L. Min, B.C. Creelan et al., The current Understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2(3), pky021 (2018). https:\/\/doi.org\/10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr."},{"issue":"2","key":"4589_CR26","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/erc-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"F. Castinetti, F. Albarel, F. Archambeaud, J. Bertherat, B. Bouillet, P. Buffier et al., French endocrine society guidance on endocrine side effects of immunotherapy. Endocr. Relat. Cancer. 26(2), G1\u2013G18 (2019). https:\/\/doi.org\/10.1530\/erc-18-0320","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04589-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:19:44Z","timestamp":1781644784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04589-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4589"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04589-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study human participants were in accordance with the 1964 Helsinki declaration and its later amendments. The study was approved by Hacettepe University Ethics Board (\n                      Study Number\n                      : SBA 25\/545,\n                      Evaluation Date\n                      : 24.06.2025) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical Standarts"}},{"value":"Informed consent was not required due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"120"}}